|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
6
|
|
pubmed:dateCreated |
2004-3-1
|
|
pubmed:abstractText |
The high prevalence of preexisting immunity to adenovirus serotype 5 (Ad5) in human populations will likely limit the immunogenicity and clinical utility of recombinant Ad5 vector-based vaccines for human immunodeficiency virus type 1 and other pathogens. Ad5-specific neutralizing antibodies (NAbs) are thought to contribute substantially to anti-Ad5 immunity, but the potential importance of Ad5-specific T lymphocytes in this setting has not been fully characterized. Here we assess the relative contributions of Ad5-specific humoral and cellular immune responses in blunting the immunogenicity of a rAd5-Env vaccine in mice. Adoptive transfer of Ad5-specific NAbs resulted in a dramatic abrogation of Env-specific immune responses following immunization with rAd5-Env. Interestingly, adoptive transfer of Ad5-specific CD8(+) T lymphocytes also resulted in a significant and durable suppression of rAd5-Env immunogenicity. These data demonstrate that NAbs and CD8(+) T lymphocytes both contribute to immunity to Ad5. Novel adenovirus vectors that are currently being developed to circumvent the problem of preexisting anti-Ad5 immunity should therefore be designed to evade both humoral and cellular Ad5-specific immune responses.
|
|
pubmed:grant |
|
|
pubmed:commentsCorrections |
http://linkedlifedata.com/resource/pubmed/commentcorrection/14990686-10400791,
http://linkedlifedata.com/resource/pubmed/commentcorrection/14990686-10906225,
http://linkedlifedata.com/resource/pubmed/commentcorrection/14990686-11689642,
http://linkedlifedata.com/resource/pubmed/commentcorrection/14990686-11777947,
http://linkedlifedata.com/resource/pubmed/commentcorrection/14990686-11797011,
http://linkedlifedata.com/resource/pubmed/commentcorrection/14990686-11812286,
http://linkedlifedata.com/resource/pubmed/commentcorrection/14990686-11861598,
http://linkedlifedata.com/resource/pubmed/commentcorrection/14990686-11861833,
http://linkedlifedata.com/resource/pubmed/commentcorrection/14990686-12133270,
http://linkedlifedata.com/resource/pubmed/commentcorrection/14990686-12477888,
http://linkedlifedata.com/resource/pubmed/commentcorrection/14990686-12538702,
http://linkedlifedata.com/resource/pubmed/commentcorrection/14990686-12743287,
http://linkedlifedata.com/resource/pubmed/commentcorrection/14990686-12743315,
http://linkedlifedata.com/resource/pubmed/commentcorrection/14990686-12857895,
http://linkedlifedata.com/resource/pubmed/commentcorrection/14990686-12885892,
http://linkedlifedata.com/resource/pubmed/commentcorrection/14990686-12904795,
http://linkedlifedata.com/resource/pubmed/commentcorrection/14990686-1372448,
http://linkedlifedata.com/resource/pubmed/commentcorrection/14990686-1376769,
http://linkedlifedata.com/resource/pubmed/commentcorrection/14990686-2555063,
http://linkedlifedata.com/resource/pubmed/commentcorrection/14990686-3373570,
http://linkedlifedata.com/resource/pubmed/commentcorrection/14990686-7533647,
http://linkedlifedata.com/resource/pubmed/commentcorrection/14990686-7884845,
http://linkedlifedata.com/resource/pubmed/commentcorrection/14990686-8810254,
http://linkedlifedata.com/resource/pubmed/commentcorrection/14990686-8825871,
http://linkedlifedata.com/resource/pubmed/commentcorrection/14990686-8867863,
http://linkedlifedata.com/resource/pubmed/commentcorrection/14990686-8989999,
http://linkedlifedata.com/resource/pubmed/commentcorrection/14990686-9032363,
http://linkedlifedata.com/resource/pubmed/commentcorrection/14990686-9499099,
http://linkedlifedata.com/resource/pubmed/commentcorrection/14990686-9525615,
http://linkedlifedata.com/resource/pubmed/commentcorrection/14990686-9681413,
http://linkedlifedata.com/resource/pubmed/commentcorrection/14990686-9811772
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Mar
|
|
pubmed:issn |
0022-538X
|
|
pubmed:author |
pubmed-author:ArthurJanelle CJC,
pubmed-author:BarouchDan HDH,
pubmed-author:GorgoneDarci ADA,
pubmed-author:GoudsmitJaapJ,
pubmed-author:HavengaMenzo J EMJ,
pubmed-author:JacksonShawn SSS,
pubmed-author:KishkoMichael GMG,
pubmed-author:KostenseStefanS,
pubmed-author:KoudstaalWouterW,
pubmed-author:LetvinNorman LNL,
pubmed-author:LiftonMichelle AMA,
pubmed-author:PauMaria GMG,
pubmed-author:SumidaShawn MSM,
pubmed-author:TruittDiana MDM
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
78
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
2666-73
|
|
pubmed:dateRevised |
2009-11-18
|
|
pubmed:meshHeading |
pubmed-meshheading:14990686-Adenovirus Infections, Human,
pubmed-meshheading:14990686-Adenoviruses, Human,
pubmed-meshheading:14990686-Adoptive Transfer,
pubmed-meshheading:14990686-Animals,
pubmed-meshheading:14990686-Antibodies, Viral,
pubmed-meshheading:14990686-CD8-Positive T-Lymphocytes,
pubmed-meshheading:14990686-Genetic Vectors,
pubmed-meshheading:14990686-HIV Envelope Protein gp120,
pubmed-meshheading:14990686-Humans,
pubmed-meshheading:14990686-Mice,
pubmed-meshheading:14990686-Mice, Inbred BALB C,
pubmed-meshheading:14990686-Neutralization Tests,
pubmed-meshheading:14990686-Serotyping,
pubmed-meshheading:14990686-Viral Vaccines
|
|
pubmed:year |
2004
|
|
pubmed:articleTitle |
Neutralizing antibodies and CD8+ T lymphocytes both contribute to immunity to adenovirus serotype 5 vaccine vectors.
|
|
pubmed:affiliation |
Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts 02215, USA.
|
|
pubmed:publicationType |
Journal Article,
Research Support, U.S. Gov't, P.H.S.,
Research Support, Non-U.S. Gov't
|
